Autologous stem cell transplantation in multiple myeloma patients with renal failure

VernacularTitle:自体干细胞移植治疗伴有严重肾功能不全的多发性骨髓瘤
Author: Wen GAO
Publication Type:Journal Article
Keywords: Multiple myeloma; Autologous; Stem cell transplantation; Kidney failure
From: Journal of Leukemia & Lymphoma 2010;19(7):441-443
CountryChina
Language:Chinese
Abstract: Renal failure is a common clinical feature in multiple myeloma (MM). The overall remission rate is 35 %-50% (complete remission is rare) in MM patients with renal failure treated by conventional chemotherapy. Many centers use high dose chemotherapy and autologous stem cell transplantation (ASCT) for the treatment of MM patients with renal failure. The current study showed that the severity of renal function damage and dialysis had no impact on stem cell mobilization and implantation. High dose melphalan and ASCT could increase the rates of complete remission, event free survival and overall survival to 30 %, about 20 and 40 months longer, respectively and some patients discontinued dialysis. However there are many problems in this area, such as a higher treatment related mortality leaded by APBSCT. In addition, the role of new agents, such as thalidomide, bortezomib and lenalidomide, require evaluation in MM patient with renal failure.